These effects were evident by improved histologic scoring (decreased steatosis, inflammation, and hepatocyte ballooning), reflected in improved NAFLD activity scores (the histological assessment of MASLD), reduced liver collagen content (including a remarkable minimal visible fibrosis in rats receiving TAA and a CCL24-blocking antibody), reduced expression of liver inflammatory (IL6) and fibrotic genes (including TIMP1, Col1a1, and TGFβ), and reduced serum levels of liver enzymes and bilirubin. The gene discussed is CCL24; the disease is metabolic dysfunction-associated steatotic liver disease.